Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00687674 · OUTCOME

Number of Participants With a Grade 3 and 4 Adverse Event (Phase I)

Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2019-08-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
up to 3 years

What was measured

Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3. Description of Grades: Grade 1: Mild Grade 2: Moderate Grade 3: Severe Grade 4: Life-threatening Grade 5: Death

Analysis population: One participant refused further treatment prior to being assessed for adverse events.

Groups in this outcome

Sorafenib + Lenalidomide + Dexamethasone

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Sorafenib + Lenalidomide + Dexamethasone12

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Sorafenib + Lenalidomide + Dexamethasone11Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        11
denoms
  1. counts
    1. group Id
      OG000
      value
      12
    units
    Participants
description
Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3. Description of Grades: Grade 1: Mild Grade 2: Moderate Grade 3: Severe Grade 4: Life-threatening Grade 5: Death
groups
  1. id
    OG000
    title
    Sorafenib + Lenalidomide + Dexamethasone
param Type
NUMBER
population Description
One participant refused further treatment prior to being assessed for adverse events.
reporting Status
POSTED
time Frame
up to 3 years
title
Number of Participants With a Grade 3 and 4 Adverse Event (Phase I)
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice